Physician profile
Cathleen Cassie
NPI 1588220966
$5,375.34
in general payments reported to CMS, 2019-2025
24 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $705 · 2023: $1,281 · 2024: $800 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,308 · Travel and Lodging: $705 · Education: $20.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.39 |
| Travel and Lodging | $704.52 |
| Education | $20.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,013.58 | 2025 | General - Therapies |
| Abbvie INC. | $970.95 | 2021-2025 | |
| Gilead Sciences, INC. | $796.61 | 2022-2025 | Livdelzi, Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $710.84 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $636.51 | 2021-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $200.43 | 2021-2023 | Ocaliva |
| Janssen Biotech, INC. | $193.72 | 2022-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $176.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $98.32 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $90.83 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $89.79 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $60.77 | 2025 | Iqirvo |
| Lilly USA, LLC | $53.84 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $46.10 | 2025 | Voquezna |
| Genzyme Corporation | $42.38 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $36.99 | 2021-2023 | |
| Qol Medical, LLC | $23.79 | 2021 | |
| Merck Sharp & Dohme LLC | $21.80 | 2021 | |
| Ardelyx, INC. | $21.22 | 2025 | Ibsrela |
| Celltrion USA INC. | $20.41 | 2024 | Zymfentra |
| Celgene Corporation | $19.97 | 2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $17.45 | 2023 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.80 | 2023 | Cyltezo |
| Sandoz INC. | $16.11 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Cassie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.